Mont-Saint-Guibert (Belgium), December 8, 2023, 10.30pm CET / 4.30pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.
On December 6, 2023, Nyxoah received a transparency notification from Deerfield Partners, L.P. indicating that Deerfield Partners, L.P. crossed the 3% threshold on November 30, 2023, after which Deerfield Partners, L.P. holds 856,085 shares, representing 2.99% of the total number of voting rights on November 30, 2023 (28,673,985).
The notification dated December 6, 2023 contains the following information:
A) Voting rights | Previous notification | After the transaction | |||
# of voting rights | # of voting rights | % of voting rights | |||
Holders of voting rights | Linked to securities | Not linked to the securities | Linked to securities | Not linked to the securities | |
James E. Flynn | 0 | 0 | 0 | 0.00% | 0.00% |
Deerfield Partners, L.P. | 899,300 | 856,085 | 0 | 2.99% | 0.00% |
Subtotal | 899,300 | 856,085 | 2.99% | ||
TOTAL | 856,085 | 0 | 2.99% | 0.00% |
Contact:
Nyxoah
David DeMartino, Chief Strategy Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1 310 310 1313
Last Trade: | US$7.80 |
Daily Change: | -0.52 -6.25 |
Daily Volume: | 44,706 |
Market Cap: | US$291.950M |
March 26, 2025 March 13, 2025 February 19, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load